Search Results for: "Clinic Roundup"
-
Clinic Roundup
Data showed the drug, at doses of 0.2 mg and 0.4 mg, proved superior to placebo after four weeks in reducing the number of micturitions per day, the main endpoint of the studyBioWorld Today | Thursday, April 11, 2013 -
Clinic Roundup
The primary endpoint of the study is the induction of clinical remission at week 12BioWorld Today | Tuesday, April 9, 2013 -
Clinic Roundup
The primary endpoint of the study is progression-free survival, and results are expected in early 2014BioWorld Today | Friday, March 1, 2013 -
Clinic Roundup
The primary endpoint of the studies will be the proportion of patients with viral load < 50 copies/mL at 48 weeks of treatmentBioWorld Today | Friday, January 25, 2013 -
Clinic Roundup
Results showed that patient groups in the evaluable per protocol population that added Cycloset to their treatment regimens achieved a 0.60 percent to 0.70 percent reduction in HbA1c (p < 0.0001) relative to placebo after 24 weeks, hitting the primary endpoint of the studyBioWorld Today | Thursday, January 24, 2013 -
Clinic Roundup
The primary endpoints of the study are mean change from baseline in inferior corneal staining score and mean eye dryness score at 12 weeksBioWorld Today | Wednesday, January 9, 2013 -
Clinic Roundup
Top-line data revealed that at the early clinical evaluation point, between 48 hours and 72 hours of treatment initiation, 90.9 percent of subjects were considered to be stable or improving in investigator assessments, meeting the primary endpoint of the studyBioWorld Today | Tuesday, January 8, 2013 -
Clinic Roundup
The primary endpoint of the study is overall survivalBioWorld Today | Thursday, December 27, 2012 -
Clinic Roundup
The primary endpoint of the study is immune-related progression-free survival at six monthsBioWorld Today | Friday, December 14, 2012 -
Clinic Roundup
The primary endpoint of the study is overall survival, and the objective is to demonstrate superiority of elacytarabine over current therapies...The primary endpoints of the study are safety and the change in peak walking time at six months compared to baselineBioWorld Today | Friday, December 7, 2012 -
Clinic Roundup
The primary endpoint of the study was controlling growth or recurrence of the cancer six months after treatment, equivalent to surgery as compared to historical controlsBioWorld Today | Thursday, November 15, 2012 -
Clinic Roundup
The primary endpoint of the study is clinical benefit of AEZS-108BioWorld Today | Tuesday, November 13, 2012 -
Clinic Roundup
The primary endpoint for the study is change in percent "off" time during waking hours, as measured by patient self-assessment during the treatment period relative to the baseline periodBioWorld Today | Friday, November 9, 2012 -
Clinic Roundup
The study showed that RLX030, a recombinant form of human hormone relaxin-2, significantly reduced dyspnea, the most common symptom of AHF and the primary endpoint of the studyBioWorld Today | Thursday, November 8, 2012 -
Clinic Roundup
The primary endpoint of the study is the time to occurrence of major adverse cardiovascular events during randomized treatment for Contrave compared to placeboBioWorld Today | Thursday, September 6, 2012 -
Clinic Roundup
The primary endpoint of the study of the targeted topoisomerase I inhibitor is the six-week progression-free survival rateBioWorld Today | Wednesday, August 8, 2012 -
Clinic Roundup
The primary endpoint of the study is objective response rateBioWorld Today | Friday, August 3, 2012 -
Clinic Roundup
The primary endpoint of the study is safety and tolerability at 12 months following the procedureBioWorld Today | Tuesday, July 31, 2012 -
Clinic Roundup
Overall survival was a secondary endpoint in the study, which previously met its progression-free survival primary endpointBioWorld Today | Monday, June 25, 2012 -
Clinic Roundup
The primary endpoint of the study was the rate of complete remission (CR) and complete remission with partial hematologic recovery (CRhBioWorld Today | Monday, June 18, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.